Epicore BioNetworks IncTSXV: EBN

Epicore BioNetworks Inc. Reports Strong Results in 2009 Quarter One

· Issued by Epicore BioNetworks Inc via CNW

for the period ended 30 September 2008

CALGARY, Nov. 26 /CNW/ - Epicore BioNetworks Inc. experienced strong business growth in quarter one fiscal 2009 despite challenging market conditions and a near collapse of the world financial system. Revenue increased by 31% compared to prior year quarter one and set a new quarter one record. Some highlights were:

-   Increased net income to $0.18 million compared to $0.04 in prior year
    quarter one.
-   Achieved net income as a percentage of sales revenue of 22%.
-   Grew basic and diluted earnings from $0.002 per share in prior year
    to $0.008.
-   Grew sales revenues by $0.2 million (31%) beating a prior year record
    quarter one.
-   Increased total stockholders equity to $2.2 million from $2.0 million
    in the last quarter and $1.5 million in prior year quarter one.
-   Increased cash by $0.2 million compared to prior year quarter one.

Aquaculture remains the Company's strongest market sector, producing 94% of total sales. Epicore biotechnology and specialty feed technology offer answers to problems of pollution, disease and poor nutrition in aquaculture operations around the world and the Epicore product range offers strong value to a growing customer base. Quarter one saw a significant increase in Epicore agricultural sales and revenue from this growing sector.

After months of torrential rains earlier this year, Ecuador recovered and contributed significantly to sales revenue during quarter one. The rest of Latin America also produced strong sales making it the most important market in the period. Distributors in Mexico, Indonesia, Brazil, India and Thailand made major contributions to fiscal 2008 results.

Epicore gross profit increased in proportion to the increases in sales, and operating expenses decreased by 10% in quarter one. Revenue growth resulted in higher income taxes, which were partially decreased by our accumulated net operating losses. The Company generated a net income of $0.18 million, more than a four fold increase over the prior year.

                                          (US$)       2008         2007
                                                      ----         ----

Sales                                               808,000      616,000
Gross Profit                                        524,000      399,000
Expenses                                            313,000      346,000
Other Income (Expense)                               (9,000)      (8,000)
Income Taxes                                         26,000        5,000
Net Income                                          178,000       40,000

Cash at the end of June was $0.7 million, an increase of $0.2 million from the prior year but a decrease of $0.1 million from fiscal 2008 year-end; this was mainly due to working capital increases. With these funds, expected sales revenue growth and continued relatively low operating costs, management expects there will be sufficient cash to meet the fiscal year's financial requirements. Additional funds will go toward expansion of aquaculture and environmental remediation marketing efforts and investigating new strategies for enhancing shareholder value.

The financial statements of the Company have been prepared in accordance with Canadian GAAP. Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). (The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.)

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.

Epicore BioNetworks Inc on 6ix

Earlier from Epicore BioNetworks

Later from Epicore BioNetworks

All Epicore BioNetworks news releases